Leerink Partners Begins Coverage on Obsidian Therapeutics (NASDAQ:OBX)

Research analysts at Leerink Partners assumed coverage on shares of Obsidian Therapeutics (NASDAQ:OBX) in a research note issued on Tuesday, Benzinga reports. The firm set an “outperform” rating and a $32.00 price target on the stock. Leerink Partners’ target price points to a potential upside of 84.65% from the company’s current price.

Several other equities research analysts have also issued reports on the stock. Lifesci Capital started coverage on shares of Obsidian Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 target price for the company. Zacks Research raised shares of Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. Weiss Ratings initiated coverage on shares of Obsidian Therapeutics in a research report on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. William Blair began coverage on shares of Obsidian Therapeutics in a research report on Wednesday, September 9th. They issued an “outperform” rating for the company. Finally, Piper Sandler assumed coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 target price on the stock. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Obsidian Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Obsidian Therapeutics Stock Performance

NASDAQ:OBX opened at $17.33 on Tuesday. Obsidian Therapeutics has a twelve month low of $14.57 and a twelve month high of $49.97.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.